Clareo Health | Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma
Radiation indication validated by a multidisciplinary meeting
Adequate contraceptive method for the whole study duration and for up to 28 days after the end of radiation
Mandatory affiliation with a health insurance company
Patients must provide dated \& written consent
You may not be if
Prior surgery for NSCLC
NSCLC nearby pulmonary apex or strictly intra-thoracic with no intra-parenchyma portion
Metastatic disease or N3 contralateral lymph node
History of chest irradiation
History of known increased intrinsic radiosensibility
Hypersensibility to active substance or excipient of fluoro-deoxyglucose-18F
Life expectancy \< 6 months
Patient with a concurrent malignancy or with a history of malignancy (excepted adequately treated basal cell skin carcinoma or cervical squamous cell carcinoma or other malignancies free of the disease for at least 5 years)
Pregnant or breastfeeding women
Psychological, sociological or geographical conditions that would limit compliance with study requirements
Patient deprived of freedom
Patient has concomitant participation to an other investigational study
